Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Drug Profile

PEGylated haemoglobin and carbon monoxide - Prolong Pharmaceuticals

Alternative Names: PEG haemoglobin; PEG haemoglobin carbon monoxide; PEG-bHb-CO; PEG-COHb; PEG-haemoglobin-CO; PEG-Hb; PEG-LEH; Pegylated carboxyhemoglobin bovine; Pegylated haemoglobin carbon monoxide; Polyethylene glycol modified bovine haemoglobin; Sanguinate

Latest Information Update: 05 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enzon Pharmaceuticals; Rutgers
  • Developer Prolong Pharmaceuticals
  • Class Haemoglobins; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Delayed graft function
  • Phase II Cerebral ischaemia; Sickle cell anaemia
  • Phase I Hypoxia
  • Clinical Phase Unknown Beta-thalassaemia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 May 2018 Prolong Pharmaceuticals withdraws a phase II trial for Delayed graft function in Brazil prior to enrolment (NCT02658162)
  • 03 Jan 2018 Phase I development in Hypoxia is ongoing (Prolong Pharmaceuticals pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top